{
    "output": [
        [
            "Adaptimmune Therapeutics plc",
            "ORG",
            "Announce",
            "Paul Stead",
            "PERSON"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Join",
            "Adaptimmune Therapeutics plc",
            "ORG"
        ],
        [
            "Adaptimmune Therapeutics plc",
            "ORG",
            "Operate_In",
            "T-cell therapy to treat cancer",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Has",
            "Tremendous wealth of business development experience",
            "CONCEPT"
        ],
        [
            "Adaptimmune Therapeutics plc",
            "ORG",
            "Focused_On",
            "Data delivery from wholly owned assets",
            "CONCEPT"
        ],
        [
            "Adaptimmune Therapeutics plc",
            "ORG",
            "Must_Evaluate",
            "Broad range of technology partnerships",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Extensive experience in business development and competitive intelligence",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Join_From",
            "Inovio Pharmaceuticals, Inc.",
            "ORG"
        ],
        [
            "Inovio Pharmaceuticals, Inc.",
            "ORG",
            "Operate_In",
            "Developing DNA-based immunotherapies within oncology and infectious diseases",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Played_Key_Role",
            "Gilead\u2019s acquisition of Nimbus\u2019s Comprised Acetyl CoA Carboxylase Inhibitors Program for treatment of NASH and related disorders",
            "CONCEPT"
        ],
        [
            "Nimbus Therapeutics LLC",
            "ORG",
            "Operate_In",
            "Gilead\u2019s acquisition of Nimbus\u2019s Comprised Acetyl CoA Carboxylase Inhibitors Program for treatment of NASH and related disorders",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Joined",
            "GlaxoSmithKline plc as a Senior Scientist in Chemistry BioProcess Development",
            "CONCEPT"
        ],
        [
            "GlaxoSmithKline plc",
            "ORG",
            "Operate_In",
            "Natural Product Chemistry Department",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Lead",
            "Competitive and Scientific Intelligence in the US",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Worked_Up_Through",
            "Technology licensing, and senior business development roles in GSK Worldwide Business Development Transactions",
            "CONCEPT"
        ],
        [
            "Paul Stead",
            "PERSON",
            "Worked_Up_Through",
            "Platform Technology and Science Business Development",
            "CONCEPT"
        ],
        [
            "Adaptimmune",
            "ORG",
            "Is_Member_Of",
            "Clinical-stage biopharmaceutical company",
            "CONCEPT"
        ],
        [
            "Adaptimmune",
            "ORG",
            "Focused_On",
            "Development of novel cancer immunotherapy products",
            "CONCEPT"
        ],
        [
            "Adaptimmune",
            "ORG",
            "Uses",
            "SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform",
            "CONCEPT"
        ],
        [
            "Adaptimmune",
            "ORG",
            "Engineering",
            "T-cells to target and destroy cancer, including solid tumors",
            "CONCEPT"
        ],
        [
            "Adaptimmune",
            "ORG",
            "Conducting_Clinical_Trials",
            "SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications",
            "CONCEPT"
        ],
        [
            "GlaxoSmithKline plc",
            "ORG",
            "Exercised_Option",
            "Exclusively license the right to research, develop, and commercialize Adaptimmune\u2019s NY-ESO SPEAR T-cell therapy program",
            "CONCEPT"
        ],
        [
            "Adaptimmune",
            "ORG",
            "Located_In",
            "Philadelphia, USA and Oxfordshire, U.K",
            "GPE"
        ],
        [
            "Adaptimmune",
            "ORG",
            "Has_Website",
            "<http://www.adaptimmune.com>",
            "CONCEPT"
        ]
    ]
}